An Efficacy and Safety Study for Tapentadol Extended Release (JNS024ER) in Chronic Pain Participants

PHASE2CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
PainLow Back PainBack PainOsteoarthritis, Knee
Interventions
DRUG

Tapentadol Hydrochloride

Tapentadol hydrochloride extended release (ER) tablets 25 to 250 milligram (mg) will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.

DRUG

Placebo

Placebo matched to tapentadol hydrochloride ER tablets 25 to 250 mg will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.

Trial Locations (19)

Unknown

Aichi

Amagasaki

Chiba

Chikushi

Edogawa City

Fukuoka

Fukushima

Hiratsuka

Kawasaki

Kōtō City

Matsudo

Meguro City

Minatoku

Niigata

Osaka

Sagamihara

Shibuya City

Shinjuku-Ku

Toshima-Ku

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY